Infectious Complications in Autoimmune Hemolytic Anemia

Area of Science:

• Hematology
• Immunology
• Infectious Diseases

Background:

• Autoimmune hemolytic anemia (AIHA) patients face high risks of infectious complications.
• Infections can trigger AIHA onset and relapse, posing significant mortality risks.
• These infectious risks are often underestimated in AIHA management.

Purpose of the Study:

• To review the frequency and types of infections in AIHA patients.
• To detail infection risks associated with various AIHA treatments, including steroids, rituximab, and newer agents.
• To discuss infections in secondary AIHA and strategies for viral/bacterial reactivation.

Main Methods:

• Systematic review of available evidence on infectious complications in AIHA.
• Analysis of treatment-specific risks (steroids, rituximab, splenectomy, etc.).
• Examination of infections in AIHA secondary to other conditions and reactivation risks.

Main Results:

• Infectious complications are frequent in AIHA, particularly with immunosuppressive therapy.
• Specific treatments like rituximab and splenectomy carry distinct infection profiles.
• Secondary AIHA and reactivation of latent infections are significant concerns.

Conclusions:

• Infections represent a critical, often underestimated, challenge in AIHA management.
• Understanding treatment-specific risks is crucial for patient care.
• Prophylactic and screening strategies are essential to mitigate infectious risks in AIHA.